Edition:
United States

Emergent BioSolutions Inc (EBS.N)

EBS.N on New York Stock Exchange

32.11USD
26 May 2017
Change (% chg)

$1.91 (+6.32%)
Prev Close
$30.20
Open
$30.70
Day's High
$32.58
Day's Low
$30.64
Volume
163,000
Avg. Vol
98,836
52-wk High
$44.29
52-wk Low
$24.48

Latest Key Developments (Source: Significant Developments)

Emergent Biosolutions reports Q1 revenue $116.9 million
Thursday, 4 May 2017 04:15pm EDT 

May 4 (Reuters) - Emergent Biosolutions Inc :Emergent Biosolutions reports first quarter 2017 financial results; reaffirms 2017 guidance.Q1 earnings per share $0.23.Q1 revenue $116.9 million versus I/B/E/S view $116.2 million.Q1 earnings per share view $0.30 -- Thomson Reuters I/B/E/S.Emergent Biosolutions Inc - Sees Q2 2017 total revenue of $100 to $115 million.Q2 revenue view $122.3 million -- Thomson Reuters I/B/E/S.  Full Article

Emergent Biosolutions signs $53 mln modification to Barda contract for manufacture of botulism antitoxin
Friday, 31 Mar 2017 07:00am EDT 

Emergent Biosolutions Inc : Emergent Biosolutions signs $53 million modification to Barda contract for the manufacture of botulism antitoxin .Emergent Biosolutions - modification to contract will enable future filling and deliveries of final drug product to strategic national stockpile.  Full Article

Emergent Biosolutions reports Q4 EPS $0.67
Thursday, 23 Feb 2017 04:15pm EST 

Emergent Biosolutions Inc : Fy2017 earnings per share view $2.08, revenue view $543.1 million -- Thomson Reuters I/B/E/S . Emergent Biosolutions reports fourth quarter and twelve months 2016 financial results; reaffirms 2017 guidance and provides 2020 goals . Q4 earnings per share $0.67 .Q4 earnings per share view $0.48 -- Thomson Reuters I/B/E/S.  Full Article

Emergent BioSolutions receives German Federal Ministry of Health Approval of Building 55 for large-scale manufacturing of BioThrax
Friday, 27 Jan 2017 07:00am EST 

Emergent BioSolutions Inc : Emergent BioSolutions receives German Federal Ministry of Health Approval of Building 55 for large-scale manufacturing of BioThrax . Emergent BioSolutions Inc - Approval allows Emergent to market BioThrax (Anthrax Vaccine Adsorbed) manufactured in Building 55 in Germany .Emergent BioSolutions Inc - "Company believes it is well-positioned to pursue BioThrax licensure across targeted countries within European Union".  Full Article

Emergent Biosolutions announces preliminary 2016 financial results
Monday, 9 Jan 2017 07:00am EST 

Emergent Biosolutions Inc : Emergent Biosolutions announces preliminary 2016 financial results and provides 2017 financial outlook . Sees Q1 2017 revenue $120 million to $135 million . Sees FY 2016 revenue $500 million to $505 million . Emergent Biosolutions sees 2017 total revenue $500 million - $530 million; 2017 net income $60 million- $70 million; 2017 biothrax sales $265 million - $280 million .For full year 2016, company anticipates cash and cash equivalents at year end of approximately $270 million.  Full Article

Emergent BioSolutions says signs follow-on contract with CDC valued at up to $911 mln
Thursday, 8 Dec 2016 05:13pm EST 

Emergent BioSolutions Inc : Emergent biosolutions - signs follow-on contract with cdc valued at up to $911 million to supply to sns about 29.4 million doses of biothrax through sept 2021 . Emergent biosolutions to support hhs anthrax preparedness strategy with up to $1 billion in biothrax deliveries to strategic national stockpile . Company re-establishes 2016 financial guidance . Emergent biosolutions inc - barda issues notice of intent to separately procure about $100 million of biothrax for sns over 24 months from contract award . Sees 2016 total revenue on a combined basis $485mln to $505mln .Sees 2016 adjusted net income on a combined basis $55mln to $65mln.  Full Article

Integrated Biotherapeutics says licensing agreement with Emergent BioSolutions
Tuesday, 15 Nov 2016 09:49am EST 

Integrated Biotherapeutics: financial terms of agreement are not disclosed .Integrated Biotherapeutics, Inc announces licensing agreement with emergent biosolutions for development of equine immunoglobulin therapeutics for filovirus infections.  Full Article

Emergent awarded BARDA contract for advanced development of NuThrax
Friday, 30 Sep 2016 09:04am EDT 

Emergent Biosolutions Inc : Awarded BARDA contract for advanced development and delivery of NuThrax, a next generation anthrax vaccine, valued at up to $1.6 billion . Contract includes options for an additional clinical study and post-marketing commitments valued at $48 million . Company anticipates that FDA could authorize NuThrax for emergency use as early as 2018 .Contract includes options for delivery of additional 7.5 million to 50 million doses of NuThrax, valued about $255 million to up to $1.4 billion.  Full Article

Pharmathene says "protests" Dept of Health and Human Services anthrax vaccine solicitation
Friday, 5 Aug 2016 12:56pm EDT 

Pharmathene Inc: "Formal protest" against Department of Health and Human Services, challenging solicitation for "next-generation anthrax vaccine provider" . As per complaint, government's "request for proposals" written in a way that assures source award to Emergent Biosolutions, which makes anthrax vaccine ."Protest requests GAO suspend award under solicitation while it reviews Pharmathene's complaint".  Full Article

Emergent BioSolutions Q2 GAAP loss per share $0.27
Thursday, 4 Aug 2016 04:15pm EDT 

Emergent Biosolutions Inc : Emergent BioSolutions reports second quarter and six months 2016 financial results . Q2 revenue $101.5 million versus i/b/e/s view $111.2 million . Q2 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S . Q2 GAAP loss per share $0.27 .Will continue to temporarily postpone its financial guidance for 2016 until further clarity is reached U.S. Government contracts.  Full Article

More From Around the Web

BRIEF-Emergent Biosolutions reports Q1 revenue $116.9 million

* Emergent Biosolutions reports first quarter 2017 financial results; reaffirms 2017 guidance